Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

Original reporting
Published Nov 5, 2026, 3:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adaptive (ADPT) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ADPTBullishHigh
01

Why it matters

The guidance lift reflects robust demand for clonoSEQ testing, likely supporting the stock price in the short term.

02

Market read

Guidance raise after strong Q3 results is a material catalyst for Adaptive and its sector.

03

What to watch

Potential delays in payer coverage expansions could limit revenue upside.

Relevance 7/10Novelty 8/10Timing: after‑hours today

Background

Adaptive (ADPT) provided its Q3 2026 earnings call, highlighting strong volume growth, a $270 M backlog, and raised full‑year MRD revenue guidance.

Company-level read

Ticker impact

$ADPTBullishHigh confidence
Context

Adaptive raised its full‑year 2026 MRD revenue guidance after reporting 46% YoY clinical volume growth and a $270 M backlog.

Expected impact

upward pressure as investors price in stronger revenue outlook

Evidence & confidence

The company disclosed higher clinical testing volumes and a sizable backlog, prompting an upward revision of full‑year revenue guidance, which typically lifts the share price.

Market effects

Boosts outlook for the molecular diagnostics and precision oncology sector.

Positive for U.S. biotech investors.

May influence global MRD testing market sentiment.

Counterpoint

If reimbursement pressures intensify, the guidance raise may be premature.

Key entities

  • Adaptive

    US‑listed biotech focused on MRD testing.

Related articles

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.

$ADPTHighAI 8/10

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet